PHIO MEXC RealStocks
Own real PHIO shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-15 19:45:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Phio Pharmaceuticals Corp. (PHIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.79, with a market capitalization of $9.21M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.75 to $1.88. This page covers its latest market performance, valuation, price trends and company information.
$9.21M | |
$0.81 | |
$0.85 | |
$0.77 | |
$0.81 | |
62.94K | |
120.42K | |
-- | |
$1.88 | |
$0.75 | |
-- | |
-- |
Phio Pharmaceuticals Corp. (PHIO) last closed at $0.79 as of 2026-11-14 00:06:00, down 5.03% ($0.04) from the previous close of $0.81.
During the latest regular trading session, PHIO traded between $0.77 and $0.85, with a volume of 62.94K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Phio Pharmaceuticals Corp. (PHIO) moved from $0.80 to $0.79, representing a decline of 1.25% ($0.01).
The stock traded between $0.75 and $0.90 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 83.03 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.5%
PHIO is currently trading at $0.79, placing it 3.5% of the way from its 52-week low of $0.75 to its 52-week high of $1.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Phio Pharmaceuticals Corp. (PHIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PHIO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PHIO shares and USD.
PHIO Shares to USD
1.00 PHIO shares = 0.79 USD
Calculations are estimates based on the latest available price and are for reference only.